Memon Ali Raza, Rajput Muhammad Ali, Rizwan Fazeela, Akram Muhammad, Rizwan Muhammad, Iqbal Zeemal
Department of Biochemistry, Liaquat University of Medical & Health Sciences, Jamshoro, Pakistan.
Department of Pharmacology, Multan Medical & Dental College, Multan, Pakistan.
J Taibah Univ Med Sci. 2022 Oct 8;18(2):420-426. doi: 10.1016/j.jtumed.2022.09.007. eCollection 2023 Apr.
This study was designed to assess the effects of a combination of and oil on disturbed lipid profiles in patients with type 2 diabetes mellitus (T2DM).
This randomized control trial (RCT) involved 160 patients of either sex (aged 40-60 years) with T2DM and dyslipidemia, and were equally divided into two groups. Group A patients received hypoglycemic and lipid lowering agents (Tab glimepiride 2 mg + metformin HCl 500 mg and Tab rosuvastatin 10 mg once a day orally). Patients in group B were given the same allopathic drugs as group A, in combination with and oil over a period of 6 months. Blood samples were taken at three stages of the study to allow the analysis of lipid profiles.
Analysis showed that after 3 and 6 months of treatment, the mean levels of serum cholesterol, triglycerides (TGs) and low-density lipoprotein (LDL) were reduced in both groups and that there was a highly significant (P < 0.001) decline in group B when compared to group A. High-density lipoprotein (HDL) levels increased in both groups but there was a significant (P < 0.05) increase in the group B when compared to group A. The percentage reduction was highest at 6 months of treatment for cholesterol, TGs, LDL and HDL in group B (41.5%, 45.9%, 60.4% and 58.1%, respectively).
The antihyperlipidemic activity observed may be due to the presence of antioxidants in the test substances. Further studies should be conducted with a larger sample size in order to further evaluate the role of powder and oil in patients with T2DM with dyslipidemia.
本研究旨在评估[具体物质1]和[具体物质2]油联合使用对2型糖尿病(T2DM)患者紊乱血脂谱的影响。
这项随机对照试验(RCT)纳入了160例年龄在40 - 60岁之间、患有T2DM和血脂异常的患者,将其平均分为两组。A组患者接受降糖和降脂药物治疗(口服格列美脲片2毫克 + 盐酸二甲双胍500毫克以及瑞舒伐他汀片10毫克,每日一次)。B组患者除接受与A组相同的对抗疗法药物外,还联合服用[具体物质1]和[具体物质2]油,为期6个月。在研究的三个阶段采集血样,以分析血脂谱。
分析表明,治疗3个月和6个月后,两组患者的血清胆固醇、甘油三酯(TGs)和低密度脂蛋白(LDL)平均水平均有所降低,且与A组相比,B组的降低幅度具有高度显著性(P < 0.001)。两组患者的高密度脂蛋白(HDL)水平均有所升高,但与A组相比,B组的升高具有显著性(P < 0.05)。B组在治疗6个月时,胆固醇、TGs、LDL和HDL的降低百分比最高(分别为41.5%、45.9%、60.4%和58.1%)。
观察到的抗高血脂活性可能归因于受试物质中存在抗氧化剂。应进行更大样本量的进一步研究,以进一步评估[具体物质1]粉和[具体物质2]油在患有血脂异常的T2DM患者中的作用。